Evidence map›Paper›PMID 27765883›Full record

ArticleJournal of the renin-angiotensin-aldosterone system : JRAAS2016

Inhibitory effects of telmisartan on culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4+ T lymphocytes from Xinjiang Kazakh patients with hypertension.

Sha-Sha Huang, Qiu-Bing Zhang, Qing-Yan Yuan, Si-Li He, Yuan-Ming Zhang

Open access · hybridAbstract read
In one paragraph

Article in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sha-Sha HuangHeart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
Qiu-Bing ZhangHeart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
Qing-Yan YuanHeart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
Si-Li HeHeart Centre, First Affiliated Hospital of Xinjiang Medical University, China.
Yuan-Ming ZhangHeart Centre, First Affiliated Hospital of Xinjiang Medical University, China 13999867798@163.com.
First Affiliated Hospital of Xinjiang Medical University · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionActivation of T lymphocytes, for which potassium channels are essential, is involved in the development of hypertension. In this study, we explored the inhibitory effects of telmisartan on the culture and proliferation of and Kv1.3 potassium channel expression in peripheral blood CD4

methodsCD4

resultsThe IL-6 and IL-17 expression levels were significantly higher in the blood of the hypertensive Kazakh patients than in the healthy Kazakh people. Telmisartan inhibited T-lymphocytic proliferation, as well as the mRNA and protein expression of the Kv1.3 potassium channel in CD4

conclusionsTelmisartan may potentially regulate hypertensive inflammatory responses by inhibiting T-lymphocytic proliferation and Kv1.3 potassium channel expression in CD4

Indexed as

EthnicityBenzimidazolesBenzoatesBlotting, WesternCase-Control StudiesCD4-Positive T-LymphocytesCell ProliferationCells, CulturedCell ShapeChinaDemographyFemaleHumansHypertensionInterleukin-17Interleukin-6BenzimidazolesBenzoatesIL6 protein, humanInterleukin-17Interleukin-6Kv1.3 Potassium ChannelRNA, MessengerTelmisartanCD4+ T Lymphocytesessential hypertensionKv1.3 potassium channeltelmisartanXinjiang Kazakh

Identifiers

PMID27765883
PMCPMC5843919
OpenAlexW2534085332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.